11a PST January 26th, 2017

This webinar is a continuation of the first webinar, entitled "Must-Know Finance Concepts for Life Sciences Valuations," and goes into more detail on the key concepts and most common methodologies used to evaluate life sciences assets.

Part 2 will discuss:

  • Which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions?
  • An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital and present value
  • What are some cash flow examples for a situation when the asset is early in the product lifecycle, for out-licensed, and for in-licensed products?
  • How do my expected deal terms relate to my forecast cash flows? How can I use this to make better decisions on licensing timing?
  • And more.

If you are an entrepreneur who plans to raise (or currently is raising) financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the life sciences investing sector, you'll benefit from this more detailed explanation of life sciences valuation methodologies.

register for
the web panel

 


 

ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.